
Release date: 2024-08-14 17:18:01 Article From: Lucius Laos Recommended: 285
Venetoclax restores normal apoptosis of cancer cells by blocking the anti-apoptotic function of the BCL-2 protein. Indications include chronic lymphocytic leukemia, acute myeloid leukemia, etc.
The precautions that patients should know before using the medication as prescribed are as follows:
In one study, venetoclax was found to be used in combination with bortezomib and dexamethasone to increase mortality in patients with multiple myeloma. Therefore, the combination of venetoclax with bortezomib and dexamethasone is not recommended for the treatment of multiple myeloma, except in controlled clinical trials.
During the treatment of chronic lymphocytic leukemia (CLL) with venetoclax, 63% to 64% of patients have been observed to develop more severe neutropenia with severity of grade 3 or 4, especially in 31% to 33% of patients who experience more severe grade 4 neutropenia. Another 4% to 6% of patients may have febrile neutropenia.
This significant decrease in neutrophil levels significantly increases the risk of infection in patients, and careful infection prevention and monitoring in these patients is particularly important.
In addition to the precautions for the use of the drug, it is equally important to understand the indications for venetoclax.
Venetoclax is suitable for adult patients and is primarily used to treat chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine is indicated for adults with newly diagnosed acute myeloid leukemia (AML), particularly those over 75 years of age or who are unable to receive intensive induction chemotherapy for health reasons.
Venetoclax has shown remarkable efficacy in the treatment of related diseases, but some adverse effects are inevitable during medication:
The number of red blood cells is reduced or malfunctioning, which may make the person feel tired, weak, or dizzy. Treatment may require iron supplementation, erythropoietin, or blood transfusions.
Such as colds, sore throats or sinusitis may occur more often when the immune system is suppressed. Treatment with antibiotics or antiviral drugs is usually required.
[Warm tips] The treatment of the disease is a long-term process, and patients should maintain a positive and optimistic attitude during the treatment process, communicate with the doctor in time if there are any questions or discomforts, and obtain professional medical advice.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:1612025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:4002024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:1552025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:1742025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:1552025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1882025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:1692025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:1652025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: